DNA expression construct for the treatment of infections with leishmaniasis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 25, 2004
app pub date -
Apr 1, 2004
filing date -
Oct 2, 2001
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
DNA expression construct for the treatment of infections with leishmania, as well as a corresponding vaccine. This vaccine serves to immunise against leishmaniasis, where in particular the immunogenic p36 LACK antigen is used to elicit an immune response. As a gene shuttle, a linear double stranded, covalently closed expression cassette is employed. The gene expression construct can be attached to an oligopeptide to increase transfection efficacy. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. .sctn.1.72(b). As stated in 37 C.F.R. .sctn.1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading 'Abstract of the Disclosure.' The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully